<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ELIPHOS
                                    Â - calcium acetateÂ tabletÂ </strong><br>Carilion Materials Management<br></p></div>
<h1>Eliphos Tablets (Calcium Acetate Tablets, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<p class="First">Each white, round tablet (stamped â€œCYP 910â€?) contains 667 mg of calcium acetate, USP (anhydrous; Ca(CH3COO)2; MW = 158.17 grams) equal to 169 mg (8.45 mEq) calcium, polyethylene glycol 8000, NF; sodium lauryl sulfate, NF; and crospovidone, NF. ELIPHOS(R) (Calcium Acetate, USP) are administered orally for the control of <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> in <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">end stage renal failure</span>.
                            <span class="Bold">Description:</span><br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<p class="First">Patients with advanced <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance less than 30 mL/min) exhibit phosphate retention and some degree of <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>. The retention of phosphate plays a pivotal role in causing secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> associated with <span class="product-label-link" type="condition" conceptid="75924" conceptname="Osteodystrophy">osteodystrophy</span>, and soft-tissue calcification. The mechanism by which phosphate retention leads to <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> is not clearly delineated. Therapeutic efforts directed toward the control of <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> patients on maintenance dialysis. Calcium acetate (ELIPHOS(R) ), when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. ELIPHOS(R) is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine. Orally administered calcium acetate from pharmaceutical dosage forms has been demonstrated to be systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under nonfasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.
                            <span class="Bold">Clinical Pharmacology:</span><br><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<p class="First">ELIPHOS(R) is indicated for the control of <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> in <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">end stage renal failure</span> and does not promote aluminum absorption.
                            <span class="Bold">Indications and Usage:</span><br></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.
                            <span class="Bold">Contraindications:</span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">end stage renal failure</span> may develop <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> when given calcium with meals. No other calcium supplements should be given concurrently with ELIPHOS(R). Progressive <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> due to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of ELIPHOS(R) may be severe as to require emergency measures. Chronic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may lead to <span class="product-label-link" type="condition" conceptid="4030365" conceptname="Vascular calcification">vascular calcification</span>, and other soft-tissue calcification. The serum calcium level should be monitored twice weekly during the early dose adjustment period. Radiographic evaluation of suspect anatomical region may be helpful in early detection of soft-tissue calcification.
                            <span class="Bold">Warnings:</span><br><br><span class="Bold">The serum calcium times phosphate (CaXP) product should not be allowed to exceed 66.</span><br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<p class="First">General: Excessive dosage of ELIPHOS(R) induces <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>; therefore, early in the treatment during dosage adjustment serum calcium should be determined twice weekly. Should <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> develop, the dosage should be reduced or the treatment discontinued immediately depending on the severity of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>. ELIPHOS(R) should not be given to patients on digitalis, because <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may precipitate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. ELIPHOS(R) therapy should always be started at low dose and should not be increased without careful monitoring of serum calcium. An estimate of daily dietary calcium intake should be made initially and the intake adjusted as needed. Serum phosphorus should also be determined periodically.
                            <span class="Bold">Precautions:</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7"></a><p></p>
<p class="First">The patient should be informed about compliance with dosage instructions, adherence to instructions about diet and avoidance of the use of nonprescription antacids. Patients should be informed about the symptoms of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (see section).
                            <span class="Bold">Information for the patient:</span><span class="Bold">ADVERSE REACTIONS</span><br></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8"></a><p></p>
<p class="First">ELIPHOS(R) may decrease the bioavailability of tetracyclines.
                            <span class="Bold">Drug Interactions:</span></p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-9"></a><p></p>
<p class="First">Long term animal studies have not been performed to evaluate the carcinogenic potential, mutagenicity, or effect on fertility of calcium acetate tablets.
                            <span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span><br></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-10"></a><p></p>
<p class="First">Teratogenic Effects: Category C. Animal reproduction studies have not been conducted with calcium acetate tablets. It is also not known whether calcium acetate tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Calcium acetate tablets should be given to a pregnant woman only if clearly needed.
                            <span class="Bold">Pregnancy:</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-11"></a><p></p>
<p class="First">Safety and efficacy of calcium acetate tablets have not been established.
                            <span class="Bold">Pediatric Use:</span><br></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-12"></a><p></p>
<p class="First">Of the total number of subjects in clinical studies of calcium acetate tablets (n = 91), 25 percent were 65 and over, while 7 percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
                            <span class="Bold">Geriatric Use:</span></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-13"></a><p></p>
<p class="First">In clinical studies, patients have occasionally experienced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> during calcium acetate tablet therapy. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may occur during treatment with ELIPHOS(R) . Mild <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (Ca greater than 10.5 mg/dl) may be asymptomatic or manifest itself as <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. More severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (Ca greater than 12 mg/dl) is associated with <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Mild <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> is easily controlled by reducing the ELIPHOS(R) dose or temporarily discontinuing therapy. Severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> can be treated by acute hemodialysis and discontinuing calcium acetate tablets therapy. Decreasing dialysate calcium concentration could reduce the incidence and severity of ELIPHOS(R) induced <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>. The long-term effect of calcium acetate tablets on the progression of vascular or soft-tissue calcification has not been determined. Isolated cases of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> have been reported which may represent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.
                            <span class="Bold">Adverse Reactions:</span><br><br></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-14"></a><p></p>
<p class="First">Administration of ELIPHOS(R) in excess of the appropriate daily dosage can cause severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (See ).
                            <span class="Bold">Overdosage:</span><span class="Bold">ADVERSE REACTIONS</span><br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-15"></a><p></p>
<p class="First">The recommended initial dose of ELIPHOS(R) for the adult dialysis patient is 2 tablets with each meal. The dosage may be increased gradually to bring the serum phosphate value below 6 mg/dl, as long as <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> does not develop. Most patients require 3â€“4 tablets with each meal.
                            <span class="Bold">Dosage and Administration:</span><br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-16"></a><p></p>
<p class="First">NDC:68151-5204-0 in a PACKAGE of 1 TABLETS</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>Calcium Acetate</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9fc1ada4-9ef4-48e9-8203-32aa857d0429&amp;name=68151-5204.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ELIPHOS
                                    Â 		
					</strong><br><span class="contentTableReg">calcium acetate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-5204(NDC:63717-910)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Calcium Acetate</strong> (Calcium Cation) </td>
<td class="formItem">Calcium Acetate</td>
<td class="formItem">667Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">2mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CYP910</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-5204-0</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078502</td>
<td class="formItem">02/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-5204)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>92caf563-66f1-43d4-a842-bcde36107f7a</div>
<div>Set id: 9fc1ada4-9ef4-48e9-8203-32aa857d0429</div>
<div>Version: 2</div>
<div>Effective Time: 20110912</div>
</div>
</div>Â <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
